Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: Comparison of hapten potencies

Molecular Pharmaceutics

Volumn 6, Issue 4, 2009, Pages 1228-1236

  Yi, Young Su ^a   Ayala López, Wilfredo ^a   Kularatne, Sumith A ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Activated macrophages; Arthritis; Dinitrophenyl; Drug targeting; Fluorescein; Folate receptor; Immunotherapy; Trinitrophenyl

Indexed keywords

2,4 DINITROPHENOL; 2,4 DINITROPHENOL 1 PLUS FOLIC ACID; 2,4 DINITROPHENOL 2 PLUS FOLIC ACID; 2,4 DINITROPHENOL 3 PLUS FOLIC ACID; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID PLUS KEYHOLE LIMPET HEMOCYANIN; FOLIC ACID PUS TRINITROPHENYL; HAPTEN; IMMUNOMODULATING AGENT; KEYHOLE LIMPET HEMOCYANIN; TRINITROPHENYL; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; CELL DENSITY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; IMMUNOTHERAPY; MACROPHAGE; MYCOBACTERIUM BUTYRICUM; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SPLENOMEGALY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARRIER PROTEINS; DINITROPHENOLS; FOLIC ACID; HAPTENS; HEMOCYANIN; IMMUNOTHERAPY; MACROPHAGES; MYCOBACTERIUM; PICRATES; RATS; RATS, INBRED LEW; RECEPTORS, CELL SURFACE; SPLENOMEGALY;

EID: 68249112814     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900070b     Document Type: Article

References (38)

1. Kinne, R. W.; Brauer, R.; Stuhlmuller, B.; Palombo-Kinne, E.; Burmester, G. R. Macrophages in rheumatoid arthritis. Arthritis Res. 2000, 2 (3), 189-202.
2. Mulherin, D.; Fitzgerald, O.; Bresnihan, B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996, 39 (1), 115-124 (Pubitemid 26036386)
3. Szekanecz, Z.; Koch, A. E. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 2007, 19 (3), 289-295 (Pubitemid 46597469)
4. Brocq, O.; Millasseau, E.; Albert, C.; Grisot, C.; Flory, P.; Roux, C. H.; Euller-Ziegler, L. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Jt., Bone, Spine 2009. DOI: 10.1016/j.jbspin.2008.11.009.
5. Waugh, J.; Perry, C. M. Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 2005, 19 (3), 189-202.
6. Bendele, A. M.; Chlipala, E. S.; Scherrer, J.; Frazier, J.; Sennello, G.; Rich, W. J.; Edwards, C. K. 3rd. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 2000, 43 (12), 2648-2659
7. Schiff, M. H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 2000, 59 (1), i103-8.
8. Goldenberg, M. M. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther. 1999, 21 (9), 1497-1513 (Pubitemid 29449551)
9. Kavanaugh, A. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials. Bull. NYU Hosp. Jt. Dis. 2007, 65 (1), S16-20.
10. Pope, R. M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2002, 2 (7), 527-535 (Pubitemid 37328744)
11. Catrina, A. I.; Trollmo, C.; af Klint, E.; Engstrom, M.; Lampa, J.; Hermansson, Y.; Klareskog, L.; Ulfgren, A. K. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum. 2005, 52 (1), 61-72.
12. Paulos, C. M.; Varghese, B.; Widmer, W. R.; Breur, G. J.; Vlashi, E.; Low, P. S. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res. Ther. 2006, 8 (3), R77.
13. van der Heijden, J. W.; Oerlemans, R.; Dijkmans, B. A.; Qi, H.; van der Laken, C. J.; Lems, W. F.; Jackman, A. L.; Kraan, M. C.; Tak, P. P.; Ratnam, M.; Jansen, G. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum. 2009, 60 (1), 12-21.
14. Xia, W.; Hilgenbrink, A. R.; Matteson, E. L.; Lockwood, M. B.; Cheng, J. X.; Low, P. S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009, 113 (2), 438-446
15. Nagayoshi, R.; Nagai, T.; Matsushita, K.; Sato, K.; Sunahara, N.; Matsuda, T.; Nakamura, T.; Komiya, S.; Onda, M.; Matsuyama, T. Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2005, 52 (9), 2666-2675 (Pubitemid 41369094)
16. Nakashima-Matsushita, N.; Homma, T.; Yu, S.; Matsuda, T.; Sunahara, N.; Nakamura, T.; Tsukano, M.; Ratnam, M.; Matsuyama, T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42 (8), 1609-1616 (Pubitemid 30263627)
17. Nagai, T.; Tanaka, M.; Tsuneyoshi, Y.; Matsushita, K.; Sunahara, N.; Matsuda, T.; Yoshida, H.; Komiya, S.; Onda, M.; Matsuyama, T. In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells. Arthritis Rheum. 2006, 54 (10), 3126-3134 (Pubitemid 44622082)
18. Pastan, I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol. Immunother. 2003, 52 (5), 338-341 (Pubitemid 36578027)
19. Lu, Y.; Low, P. S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 2002, 51 (3), 153-162
20. Lu, Y.; You, F.; Vlahov, I.; Westrick, E.; Fan, M.; Low, P. S.; Leamon, C. P. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential. Mol. Pharmaceutics 2007, 4 (5), 695-706.
21. Xu, L. C.; Vlahov, I. R.; Leamon, C. P.; Santhapuram, H. K.; Li, C. Synthesis and purification of pteroic acid and conjugates thereof. PCT/US2006/009153, 2006.
22. Reddy, J. A.; Xu, L. C.; Parker, N.; Vetzel, M.; Leamon, C. P. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J. Nucl. Med. 2004, 45 (5), 857-866
23. van Eden, W.; Wagenaar-Hilbers, J. P. A.; Wauben, M. H. M., Unit 15.4 Adjuvant Arthritis in the Rat. In Current Protocols in Immunology; Coligan, J. E., Bierer, B., Margulies, D. H., Shevach, E. M., Strober, W., Coico, R., Brown, P., Donovan, J. C., Kruisbeek, A., Eds.; John Wiley & Sons: Hoboken, NJ, 1996; p 770.
24. Turk, M. J.; Breur, G. J.; Widmer, W. R.; Paulos, C. M.; Xu, L. C.; Grote, L. A.; Low, P. S. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002, 46 (7), 1947-1955
25. Fletcher, D. S.; Widmer, W. R.; Luell, S.; Christen, A.; Orevillo, C.; Shah, S.; Visco, D. Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J. Pharmacol. Exp. Ther. 1998, 284 (2), 714-721 (Pubitemid 28086663)
26. Mauritz, R.; Peters, G. J.; Kathmann, I.; Teshale, H.; Noordhuis, P.; Comijn, E. M.; Pinedo, H. M.; Jansen, G. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. Cancer Chemother. Pharmacol. 2008, 62 (6), 937-948
27. Maziarz, K. M.; Monaco, H. L.; Shen, F.; Ratnam, M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. J. Biol. Chem. 1999, 274 (16), 11086-11091 (Pubitemid 129528317)
28. Paulos, C. M.; Reddy, J. A.; Leamon, C. P.; Turk, M. J.; Low, P. S. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol. Pharmacol. 2004, 66 (6), 1406-1414
29. Wolfe, F.; Mitchell, D. M.; Sibley, J. T.; Fries, J. F.; Bloch, D. A.; Williams, C. A.; Spitz, P. W.; Haga, M.; Kleinheksel, S. M.; Cathey, M. A. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994, 37 (4), 481-494
30. Atzeni, F.; Doria, A.; Carrabba, M.; Turiel, M.; Sarzi-Puttini, P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun. Rev. 2007, 6 (8), 529-536 (Pubitemid 47374618)
31. Baraf, H. S. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr. Pharm. Des. 2007, 13 (22), 2228-2236
32. Chilton, F.; Collett, R. A. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008, 6 (1), 1-14.
33. Siddiqui, M. A. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr. Opin. Rheumatol. 2007, 19 (3), 308-313
34. Lu, Y.; Sega, E.; Low, P. S. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int. J. Cancer 2005, 116 (5), 710-719
35. Lu, Y.; Xu, L. C.; Parker, N.; Westrick, E.; Reddy, J. A.; Vetzel, M.; Low, P. S.; Leamon, C. P. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugatetargeted immunotherapy in hapten-immunized mice. Mol. Cancer Ther. 2006, 5 (12), 3258-3267
36. Varghese, B.; Haase, N.; Low, P. S. Depletion of folate-receptorpositive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus. Mol. Pharmaceutics 2007, 4 (5), 679-685
37. Paulos, C. M.; Turk, M. J.; Breur, G. J.; Low, P. S. Folate receptormediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Delivery Rev. 2004, 56 (8), 1205-1217
38. Vergunst, C. E.; Gerlag, D. M.; Lopatinskaya, L.; Klareskog, L.; Smith, M. D.; van den Bosch, F.; Dinant, H. J.; Lee, Y.; Wyant, T.; Jacobson, E. W.; Baeten, D.; Tak, P. P. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebocontrolled clinical trial. Arthritis Rheum. 2008, 58 (7), 1931-1939